Rachel A High1, William Winkelman2, Joseph Panza3, Derrick J Sanderson4, Hyde Yuen5, Gabriela Halder6, Courtney Shaver7, Erin T Bird8, Rebecca G Rogers6, Jill M Danford8. 1. Department of Obstetrics and Gynecology, Baylor Scott & White Health, 2401 South 31st Street, Temple, TX, 76508, USA. Rachel.High@bswhealth.org. 2. Department of Obstetrics and Gynecology, Mount Auburn Hospital, Cambridge, and the Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, and the Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA, USA. 3. Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Obstetrics and Gynecology University of Rochester School of Medicine & Dentistry, Rochester, NY, USA. 5. Department of Obstetrics and Gynecology, Christ Hospital, Cincinnati, OH, USA. 6. Dell School of Medicine, University of Texas, Austin, TX, USA. 7. Office of Biostatistics Baylor Scott & White, Temple, TX, USA. 8. Department of Urology Baylor Scott & White Health, Temple, TX, USA.
Abstract
OBJECTIVE: To evaluate if age and comorbidities are associated with progression from trial phase to implantation of an implantable pulse generator in women with overactive bladder. METHODS: This multisite retrospective cohort included women with overactive bladder with or without urinary incontinence who had a trial phase for sacral neuromodulation. The primary outcome was progression to implantation. A sub-analysis of implanted patients was performed for the outcome of additional therapies or "implant only" for the duration of follow-up. Multivariate logistic regression models including potential predictors of implantation and post-implantation addition of therapies were performed. RESULTS: At six academic institutions, 91% (785/864) of patients progressed to implantation. Post-implantation success was achieved by 69% (536/782) of patients at median follow-up of 2 (range 0.3 to 15) years. Odds of implantation [OR 0.73 (CI 0.61, 0.88)] and post-implantation success [OR 0.78 (CI 0.98, 0.97)] were lower with increasing decades of age. Medical comorbidities evaluated did not affect implantation rates or post-implant success. CONCLUSIONS: Most women have successful sacral neuromodulation trials despite older age and comorbidities. Higher decade of age has a negative effect on odds of implantation and is associated with addition of therapies post-implantation. Comorbidities assessed in this study did not affect implantation or addition of therapies post-implantation. Most women add therapies to improve efficacy post-implantation, and explantation rates are low.
OBJECTIVE: To evaluate if age and comorbidities are associated with progression from trial phase to implantation of an implantable pulse generator in women with overactive bladder. METHODS: This multisite retrospective cohort included women with overactive bladder with or without urinary incontinence who had a trial phase for sacral neuromodulation. The primary outcome was progression to implantation. A sub-analysis of implanted patients was performed for the outcome of additional therapies or "implant only" for the duration of follow-up. Multivariate logistic regression models including potential predictors of implantation and post-implantation addition of therapies were performed. RESULTS: At six academic institutions, 91% (785/864) of patients progressed to implantation. Post-implantation success was achieved by 69% (536/782) of patients at median follow-up of 2 (range 0.3 to 15) years. Odds of implantation [OR 0.73 (CI 0.61, 0.88)] and post-implantation success [OR 0.78 (CI 0.98, 0.97)] were lower with increasing decades of age. Medical comorbidities evaluated did not affect implantation rates or post-implant success. CONCLUSIONS: Most women have successful sacral neuromodulation trials despite older age and comorbidities. Higher decade of age has a negative effect on odds of implantation and is associated with addition of therapies post-implantation. Comorbidities assessed in this study did not affect implantation or addition of therapies post-implantation. Most women add therapies to improve efficacy post-implantation, and explantation rates are low.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Anna E R Faris; Bradley C Gill; Javier Pizarro-Berdichevsky; Elodi Dielubanza; Marisa M Clifton; Henry Okafor; Howard B Goldman; Courtenay K Moore; Raymond R Rackley; Sandip P Vasavada Journal: J Urol Date: 2017-02-10 Impact factor: 7.450
Authors: Holly E Richter; C L Amundsen; S W Erickson; J E Jelovsek; Y Komesu; C Chermansky; H S Harvie; M Albo; D Myers; W T Gregory; D Wallace Journal: J Urol Date: 2017-05-10 Impact factor: 7.450
Authors: Steven Siegel; Karen Noblett; Jeffrey Mangel; Jason Bennett; Tomas L Griebling; Suzette E Sutherland; Erin T Bird; Craig Comiter; Daniel Culkin; Samuel Zylstra; Fangyu Kan; Kellie Chase Berg Journal: J Urol Date: 2017-07-11 Impact factor: 7.450
Authors: Bradley C Gill; Javier Pizarro-Berdichevsky; Pallab K Bhattacharyya; Thaddeus S Brink; Brian K Marks; Adrienne Quirouet; Sandip P Vasavada; Stephen E Jones; Howard B Goldman Journal: J Urol Date: 2017-06-20 Impact factor: 7.450
Authors: Karin S Coyne; Chris C Sexton; Christine L Thompson; Ian Milsom; Debra Irwin; Zoe S Kopp; Christopher R Chapple; Steven Kaplan; Andrea Tubaro; Lalitha P Aiyer; Alan J Wein Journal: BJU Int Date: 2009-03-05 Impact factor: 5.588
Authors: Ranjana Jairam; Jamie Drossaerts; Tom Marcelissen; Gommert van Koeveringe; Desiree Vrijens; Philip van Kerrebroeck Journal: Urol Int Date: 2021-05-31 Impact factor: 1.934